Lv3
300 积分 2025-05-26 加入
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
23天前
已完结
Iptacopan in IgA Nephropathy — Final 24-Month Data
1个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
2个月前
已完结
A guide to complement biology, pathology and therapeutic opportunity
3个月前
已完结
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial
3个月前
已完结
First in Human Single-Ascending Dose Study: Safety, Biomarker, Pharmacokinetics and Exposure-Response Relationships of ALXN1210, a Humanized Monoclonal Antibody to C5, with Marked Half-Life Extension and Potential for Significantly Longer Dosing Intervals
4个月前
已完结
Differential acquired resistance to anti-TNF therapy in RA patients
4个月前
已完结
Are TNF inhibitors still the agent of choice for RA?
4个月前
已完结
Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?
4个月前
已完结
皖公网安备34019202002308
